Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $30

Guggenheim analyst Seamus Fernandez has reiterated a Buy rating on Amylyx Pharmaceuticals (NASDAQ: AMLX) and increased the price target from $25 to $30. This adjustment reflects a positive outlook for the company's stock performance.